These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30431570)

  • 1. A pilot study of the effect of ezetimibe for postprandial hyperlipidemia.
    Xue EZ; Zhang MH; Liu CL
    Medicine (Baltimore); 2018 Nov; 97(46):e12960. PubMed ID: 30431570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting remnant lipoproteins can predict postprandial hyperlipidemia.
    Nagata T; Sugiyama D; Kise T; Tsuji S; Ohira H; Sato I; Yamamoto M; Kohsaka H; Kawano S; Yamashita S; Ishikawa Y; Fujioka Y
    Lipids Health Dis; 2012 Oct; 11():146. PubMed ID: 23110373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
    Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
    Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
    Nozue T; Michishita I; Mizuguchi I
    J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.
    Kikuchi K; Nezu U; Inazumi K; Miyazaki T; Ono K; Orime K; Shirakawa J; Sato K; Koike H; Wakasugi T; Sato M; Kawakami C; Watanabe S; Yamakawa T; Terauchi Y
    J Atheroscler Thromb; 2012; 19(12):1093-101. PubMed ID: 22878697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk Chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese sub-population analysis].
    Han YL; Ma YY; Su GH; Li Y; Li Y; Liu DF; Song R; Li JY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):593-599. PubMed ID: 32842270
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases.
    Nakajima K; Nakajima Y; Takeichi S; Fujita MQ
    Atherosclerosis; 2008 May; 198(1):237-46. PubMed ID: 17977545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.
    Sugiyama S; Jinnouchi H; Hieshima K; Kurinami N; Suzuki T; Miyamoto F; Kajiwara K; Matsui K; Jinnouchi T
    Lipids Health Dis; 2015 Apr; 14():37. PubMed ID: 25903215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
    Savvidaki E; Koukoulaki M; Benou A; Roumeliotou M; Fourtounas C; Kalliakmani P; Papachristou E; Vlachojannis JG; Goumenos D
    Clin Nephrol; 2011 Feb; 75(2):107-12. PubMed ID: 21255539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
    Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
    Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load.
    Hiramitsu S; Miyagishima K; Ishii J; Matsui S; Naruse H; Shiino K; Kitagawa F; Ozaki Y
    J Cardiol; 2012 Nov; 60(5):395-400. PubMed ID: 22890076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial hyperlipidemia as a potential residual risk factor.
    Nakamura K; Miyoshi T; Yunoki K; Ito H
    J Cardiol; 2016 Apr; 67(4):335-9. PubMed ID: 26744235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients.
    El-Tamalawy MM; Ibrahim OM; Hassan TM; El-Barbari AA
    J Clin Pharmacol; 2018 Jan; 58(1):34-41. PubMed ID: 28858387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
    Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF
    J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.